|
As 2008 draws to a close, Express Pharma
decided to recap important milestones of this year, which
we featured through our Cover Stories and other columns. All
in all, a smorgasbord of views, reflecting the times and travails
of the Indian pharma industry in 2008.
NPIL
is now Piramal Healthcare
After 20 years of operations, Nicholas Piramal India Limited
(NPIL) is acquiring a new corporate identity—Piramal
Healthcare
Taro
calls off merger with Sun Pharma
Israel's Taro Pharmaceuticals recently terminated its merger
agreement with Sun Pharma
Ranbaxy
wins UK SFO case
Ranbaxy Laboratories announced that the UK Serious Fraud Office's
(SFO) prosecution of its UK subsidiary, Ranbaxy UK Ltd (RUKL),
has been quashed by the English Crown Court
Sun
Pharma wins case against Taro
Sun Pharmaceutical won a case in Israel which was filed against
by Taro regarding an open offer for the latter
Ranbaxy
becomes Daiichi Sankyo subsidiary
Ranbaxy Laboratories and Daiichi Sankyo announced that the
Committee of the Board of Directors of Ranbaxy approved the
allotment of equity shares and warrants on a preferential
basis to Daiichi Sankyo
Racing
to the top
With the surge of clinical research (CR) in India, the dearth
of adequately trained professionals could seriously hinder
the reputation and growth of the CR industry in India. The
fact of the matter is that India cannot afford to be left
behind and let the CR opportunity pass on to other countries.
Aashruti Kak finds out what is not going right… (Extracted
from Express Pharma, 16-31 January 2008)
Opting
for the co-opetitive approach
The risky business of drug discovery has resulted in a new
'co-opetitive' approach. Today, many Indian pharma companies
are partnering with Big Pharma, giving rise to different collaborative
drug discovery models. Arshiya Khan reveals... (Extracted
from Express Pharma, 1-15 April 2008)
Playing
on the same team
Amidst growing concern about a financial crunch and heavy
pressure to develop new molecules, the concept of public private
partnerships (PPPs) has evolved as an able rescuer to drug
developers. Sachin Jagdale reports... (Extracted from Express
Pharma, 16-30 June 2008)
The
chase begins
Strategic move or sell out, the Ranbaxy Laboratories-Daiichi
Sankyo deal could mark the beginning of a new era in the Indian
pharmaceutical market. As players realign themselves to their
new role as prey rather than predators, Arshiya Khan and Suja
Nair analyse different options... (Extracted from Express
Pharma, 1-15 July 2008)
Cementing
the gap
While trade associations act as a catalyst in boosting the
growth of the Indian pharma industry, they are also trying
hard to bridge the gap between the industry and the Government.
Arshiya Khan analyses the role of these associations... (Extracted
from Express Pharma, 1-15 August 2008)
Pharma's
new prescription—hospitals?
Is the slow down in the global pharma industry forcing Indian
companies to look more closely at hospitals? That's reason
enough for leaders of both industries to share space on the
same page. Arshiya Khan finds out more... (Extracted from
Express Pharma, 16-31 August 2008)
Reducing
patient dropouts
Is India's patient pool showing the first signs of drying
up? Or is it a case of a lack of investigators to get to the
right patients? Usha Sharma analyses... (Extracted from Express
Pharma, 1-15 September 2008)
Behind
the smokescreen
As anti-smoking campaigns become more visible, the market
for nicotine replacement therapies will also pick up. Suja
Nair explores... (Extracted from Express Pharma, 16-30 September
2008)
Are
emergency contraceptive pills a necessary evil?
Increased use of emergency contraceptive pills has become
the talk of the town. But is it really safe to pop in one
like a routine pill? Suja Nair explores... (Extracted from
Express Pharma, 16-31 April 2008)
|
